Prevention of Acute Radiation cystitis by using Intra-vesical chondroitine Sulphate.
Go to the PARIS website
To evaluate whether preventive intravesical instillations with 0.2% chondroitin sulphate solution reduce bother related to acute radiation cystitis symptoms in patients undergoing pelvic radiotherapy for a gynaecologic malignancy. In addition we aim to define if it is cost-efficient to provide this intervention to patients undergoing pelvic radiotherapy for a gynaecologic malignancy.
A double blind multicenter randomized controlled trial
Women, aged 18 years or older, who are indicated to undergo primary or adjuvant pelvic radiotherapy for a gynecologic malignancy.
Participating patients will undergo weekly intravesical instillations with chondroitin sulphate solution or physiologic sodium chloride solution during the time of radiotherapy (mostly six weeks), starting between the 1st and 3rd day of radiotherapy. The intervention group will be instilled with 0.2% chondroitin sulphate solution and the control group with physiologic sodium chloride solution
Primary objective is to evaluate whether intravesical instillations with 0.2% chondroitin sulphate solution reduce bother related to acute radiation cystitis symptoms patients undergoing pelvic radiotherapy. The main study parameter is the difference in Overactive Bladder domain score of the Urogenital Distress Inventory (UDI), measured 12 weeks after the patient received the first instillation.
Secondary objectives are to evaluate whether it is cost-efficient to provide intravesical instillations with 0.2% chondroitin sulphate solution to patients undergoing pelvic radiotherapy and to evaluate whether intravesical instillations with 0.2% chondroitin sulphate solution can reduce the prevalence of chronic radiation cystitis.
Our pilot study showed that the median overactive bladder domain score of the patients who received the instillations at four weeks was 31 (SD 26) and of the controls 50 (SD 25). Revicki and colleagues state that the difference in domain score that can be considered to be clinically relevant is half of the SD in the intervention group. Based on these 2 sources we consider a difference of 13 points in the OAB domain score of the UDI to be clinically relevant. With a power of 80%, alpha level of 0.05 and standard deviation of 26, the calculated sample size necessary is 64 in each group. Accounting for 10% drop outs we will include 140 patients in total.
The outcomes measures of the economic evaluation are, respectively, the costs per unit at the Urogenital Distress Inventory and the costs per quality adjusted life year (QALY). The time horizon is restricted to 6 months. With this short-time span, no discounting (of costs and effects) is performed. Incremental cost-effectiveness ratios are calculated, reflecting the extra costs per additional unit gained at the UDI and the extra costs per additional QALY. Sensitivity analyses will be performed to account for sampling variability (following bias corrected and accelerated non-parametric bootstrapping), for plausible ranges in unit costs medical interventions, and for different health utility algorithms (see below).
First year: start of study in all participating centers
First 18 months: inclusion of patients, data collection and entry
Last 6 months: analysis of data, preparation of manuscripts
Dr. J.P.W.R Roovers, gynaecologist, AMC Amsterdam
Prof. Dr. G.G. Kenter, gynaecological oncologist, CGOA
Dr. L.J.A. Stalpers, radiotherapist, AMC Amsterdam
Drs. M. Derks, AMC Amsterdam
Drs. M. Derks, PhD student
020-5664158; 020-5669111 pager 58180